Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on cancer immunotherapy that entered the public markets through a SPAC combination. The company filed a Form 10-Q with the Securities and Exchange Commission on August 1, 2023, reflecting its status as an active post-merger reporting company in the biotechnology and oncology sectors. Estrella's pipeline targets novel immunotherapeutic approaches to treating cancer, positioning it among a cohort of life-sciences companies that have used the SPAC route to access public capital. The filing, recorded under accession number 0001213900-23-061563, captures the company's quarterly disclosures as a SPAC-derived public entity. For full data on ESLA's deal history, filing timeline, and sponsor details, sign up at SpacDesk.